Published in Cancer Weekly, September 26th, 2000
The first clinical site has received Institutional Review Board (IRB) approval for this study.
The initial Phase I study protocol is designed to determine the maximum tolerated dose, where the dose-limiting toxicity is identified using the standard once every three weeks platinum dosing regimen. This study will be conducted at two European sites, and it is anticipated that IRB approval at the second site will be received shortly.
Polymer platinate AP 5280, a patented compound consisting of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.